• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by OptiNose Inc.

    3/26/25 7:43:46 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPTN alert in real time by email
    S-8 1 s-8optn2025evergreen.htm S-8 Document

    As filed with the Securities and Exchange Commission on March 26, 2025
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
    ______________________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    ______________________
    OptiNose, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    777 Township Line Road, Suite 300
    Yardley, Pennsylvania 19067
    42-1771610
    (State or other jurisdiction of
    incorporation or organization)
    (Address, including zip code, of Registrant’s
    principal executive offices)
    (I.R.S. Employer
    Identification No.)
    AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN
    RESTRICTED STOCK UNIT AWARD (INDUCEMENT GRANT)
    NON-QUALIFIED STOCK OPTION AWARDS (INDUCEMENT GRANT)
    (Full title of the plans)
    Ramy Mahmoud
    Chief Executive Officer
    OptiNose, Inc.
    777 Township Line Road, Suite 300
    Yardley, Pennsylvania 19067
    (267) 364-3500
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    With Copy to:
    Michael F. Marino
    Chief Legal Officer
    OptiNose, Inc.
    777 Township Line Road, Suite 300
    Yardley, PA 19067
    (267) 364-3500
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer
    ☐
    Accelerated filer
    ☐
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☒
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐



    EXPLANATORY NOTE
    Amended and Restated 2010 Stock Incentive Plan
    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering an additional 402,336 shares of common stock, par value $0.001 per share (“Common Stock") of OptiNose, Inc. (the "Registrant"), issuable pursuant to the OptiNose, Inc. Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”). These additional shares of common stock have become reserved for issuance as a result of the operation of the “evergreen” provision in the 2010 Plan, which provides that the total number of shares subject to such plan will be increased on the first day of each fiscal year pursuant to a specified formula or will be increased to such lesser total number of shares as may be determined by the Board with respect to the 2010 Plan. The contents of the previous Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on October 20, 2017 (File No. 333-221047), March 13, 2018 (File No. 333-223617), March 6, 2019 (File No. 333-230083), March 9, 2020 (File No. 333-236978), March 3, 2021 (File No. 333-253814), March 8, 2022 (File No. 333-263362), March 7, 2023 (File No. 333-270333) and March 7, 2024 (File No. 333-277746) to the extent not otherwise amended or superseded by the contents hereof, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.
    Inducement Awards
    This Registration Statement is also being filed for the purpose of registering shares of Common Stock issuable upon the vesting and settlement of restricted stock unit ("RSU") awards and the exercise of nonqualified stock option awards granted to employees of the Registrant to induce each such individual to accept employment with the Registrant (collectively, the “Inducement Awards”). The Inducement Awards were granted as detailed below:
    •award of 10,000 RSUs granted to an executive officer of the Company on October 7, 2024;
    •nonqualified stock option awards to purchase 48,830 shares of Common Stock granted on October 7, 2024; and
    •nonqualified stock option award to purchase 8,499 shares of Common Stock granted on October 14, 2024;
    The Inducement Awards were approved pursuant to delegated authority by the Registrant’s Compensation Committee of the Board of Directors in compliance with and in reliance on Nasdaq Listing Rule 5635(c)(4). The Inducement Awards were granted outside of the 2010 Plan.
    1


    PART I
    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS
    As permitted by the rules of the Commission, this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the 2010 Plan or the Inducement Awards, as applicable, as required by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3. Incorporation of Documents by Reference.
    The following documents of the Registrant filed with the Commission are incorporated by reference in this Registration Statement as of their respective dates:
    •the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 26, 2025;
    •the Registrant’s Current Report on Form 8-K filed with the Commission on March 20, 2025 and on March 20, 2025; and
    •the description of the Common Stock contained in our registration statement on Form 8-A (File No. 001-38241) filed with the Commission on October 10, 2017, as updated by Exhibit 4.5 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, including any amendments or reports filed for the purpose of updating such description.
    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are “furnished” rather than filed with the Commission.
    For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
    Item 4. Description of Securities.
    Not applicable.
    Item 5. Interests of Named Experts and Counsel.
    Not applicable.
    Item 6. Indemnification of Directors and Officers.
    We are incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such person as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses
    2


    (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses which such officer or director has actually and reasonably incurred. Our fourth amended and restated certificate of incorporation and amended and restated bylaws provide for the indemnification of our directors and officers to the fullest extent permitted under the Delaware General Corporation Law.
    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any:
    •transaction from which the director derives an improper personal benefit;
    •act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
    •unlawful payment of dividends or redemption of shares; or
    •breach of a director’s duty of loyalty to the corporation or its stockholders.
    Our fourth amended and restated certificate of incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding in advance of its final disposition shall be paid by us upon delivery to us of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by us.
    As permitted by the Delaware General Corporation Law, we have entered into indemnification agreements with our directors and executive officers. These agreements, among other things, require us to indemnify each director and officer to the fullest extent permitted by law and advance expenses to each indemnitee in connection with any proceeding in which indemnification is available.
    At present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted.
    We have an insurance policy covering our officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, or otherwise.
    Item 7. Exemption from Registration Claimed.
    Not applicable.
    3


    Item 8. Exhibits.
    Exhibit NumberDescription
    4.1
    Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on October 18, 2017)
    4.2
    Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation of OptiNose, Inc. (incorporated by reference to Exhibit 3.3 to the Registrant's Quarterly Report on Form 10-Q filed with the Commission on August 10, 2023)
    4.3
    Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of OptiNose, Inc., effective December 30, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on December 30, 2024)
    4.4
    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on October 18, 2017).
    5.1*
    Opinion of the Company's Chief Legal Officer as to the legality of the securities being registered.
    10.1
    Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-220515) filed with the Commission on October 11, 2017).
    10.2
    Form of Non-Qualified Stock Option Agreement (Inducement Grant) (incorporated by reference to Exhibit 99.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on February 19, 2020).
    10.3
    Form of Restricted Stock Unit Agreement (Inducement Grant) (incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q filed with the Commission on May 7, 2020)
    23.1*
    Consent of Ernst & Young LLP, independent registered public accounting firm.
    23.2*
    Consent of the Company's Chief Legal Officer (included in Exhibit 5.1).
    24.1*
    Power of Attorney (included on the signature page).
    107*
    Filing Fee Table
    ______________
    *Filed herewith
    Item 9. Undertakings.
    (a)     The undersigned Registrant hereby undertakes:
    (1)    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii)    To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;
    (iii)    To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;
    4


    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
    (2)    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b)    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c)    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    5


    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Borough of Yardley, Commonwealth of Pennsylvania, on the 26th day of March, 2025.

    OPTINOSE, INC.
    By:/s/ RAMY MAHMOUD
    Ramy Mahmoud
    Chief Executive Officer
    POWER OF ATTORNEY
    We, the undersigned officers and directors of OptiNose, Inc., hereby severally constitute and appoint Ramy Mahmoud and Terry Kohler, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable OptiNose, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.



    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities indicated on the dates indicated.
    SignatureTitleDate
    /s/ RAMY MAHMOUDChief Executive Officer and Director (Principal Executive Officer)March 26, 2025
    Ramy Mahmoud
     /s/ TERRY KOHLERChief Financial Officer (Principal Financial Officer and Principal Accounting Officer)March 26, 2025
    Terry Kohler
    /s/ R. JOHN FLETCHERChairman of the Board of DirectorsMarch 26, 2025
    R. John Fletcher
    /s/ ERIC BEDNARSKIDirectorMarch 26, 2025
    Eric Bednarski
    /s/ KYLE DEMPSEYDirectorMarch 26, 2025
    Kyle Dempsey
    /s/ WILHELMUS GROENHUYSEN DirectorMarch 26, 2025
    Wilhelmus Groenhuysen
    /s/ TOMAS J. HEYMAN DirectorMarch 26, 2025
    Tomas J.Heyman
    /s/ SANDRA L. HELTON DirectorMarch 26, 2025
    Sandra L. Helton

    Get the next $OPTN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPTN

    DatePrice TargetRatingAnalyst
    3/20/2025Buy → Hold
    Lake Street
    1/3/2025$5.00 → $18.00Buy
    H.C. Wainwright
    3/11/2024$5.00Buy
    H.C. Wainwright
    8/21/2023$3.00Buy
    Lake Street
    10/21/2022$5.00Buy
    Jefferies
    More analyst ratings

    $OPTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer & Corp Sec Marino Michael F Iii returned 125,204 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - OptiNose, Inc. (0001494650) (Issuer)

    5/21/25 9:26:54 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Kohler Terry returned 30,541 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - OptiNose, Inc. (0001494650) (Issuer)

    5/21/25 9:26:25 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Fletcher R John

    4 - OptiNose, Inc. (0001494650) (Issuer)

    5/21/25 9:26:21 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

    BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty

    5/21/25 8:26:34 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

    Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2024, and provided recent operational highlights. Fourth Quarter 2024 and Recent Highlights New Prescriptions (NRx) and Total Prescriptions (TRx)An inflection in prescription demand first

    3/26/25 7:00:00 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

    YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

    3/19/25 9:45:38 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    SEC Filings

    View All

    SEC Form 15-12G filed by OptiNose Inc.

    15-12G - OptiNose, Inc. (0001494650) (Filer)

    6/2/25 1:57:42 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by OptiNose Inc.

    EFFECT - OptiNose, Inc. (0001494650) (Filer)

    5/22/25 12:15:04 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by OptiNose Inc.

    EFFECT - OptiNose, Inc. (0001494650) (Filer)

    5/22/25 12:15:09 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    OptiNose downgraded by Lake Street

    Lake Street downgraded OptiNose from Buy to Hold

    3/20/25 8:56:55 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on OptiNose with a new price target

    H.C. Wainwright reiterated coverage of OptiNose with a rating of Buy and set a new price target of $18.00 from $5.00 previously

    1/3/25 7:58:58 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on OptiNose with a new price target

    H.C. Wainwright initiated coverage of OptiNose with a rating of Buy and set a new price target of $5.00

    3/11/24 7:44:36 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OptiNose Inc.

    SC 13G - OptiNose, Inc. (0001494650) (Subject)

    11/20/24 5:21:26 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

    SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

    11/14/24 4:54:20 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

    SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

    11/12/24 10:32:10 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Financials

    Live finance-specific insights

    View All

    Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

    BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty

    5/21/25 8:26:34 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

    YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

    3/19/25 9:45:38 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

    Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek's vision to become a multi-product company focused on innovative specialty therapies Total transaction value of up to ~$330 million Potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to Optinose's closing trading price on March 19, 2025 BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under w

    3/19/25 9:25:02 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Leadership Updates

    Live Leadership Updates

    View All

    Optinose Appoints Terry Kohler as Chief Financial Officer

    YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and development pipeline investments. Mr. Kohler is an experienced biotech finance leader with over 20 years of business experience. "We are pleased to add Terry to our leadership team to help guide

    10/7/24 4:59:53 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Announces CEO Transition and Business Update

    YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose. I am proud of all that we have accomplished and the impact we continue to make in our mission to improve patients' lives." During Mr. Miller's nearly 13 years as CEO, the Company experienced s

    1/31/23 7:00:00 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Appoints Paul Spence as Chief Commercial Officer

    YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 years of experience in the life science and pharmaceuticals industry as a leader responsible for marketing, sales, market access, operations, and supply chain. Prior to joining Nestlé Health Sciences,

    12/15/22 4:30:00 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care